ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,150.51
-0.92%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Arbutus Biopharma Corporation (ABUS)

  7. Arbutus Biopharma Corporation (ABUS) Noticias

ABUS Arbutus Biopharma Corporation

2.73
0.01 (0.37%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Arbutus Biopharma Corporation ABUS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.01 0.37% 2.73 16:13:59
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.73 2.70 2.78 2.73 2.72
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
18/4/202406:30GLOBEArbutus to Report First Quarter 2024 Financial Results and..
04/4/202407:30GLOBEArbutus Biopharma Announces Claim Construction Ruling in its..
08/3/202406:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
05/3/202415:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202406:31EDGAR2Form 8-K - Current report
29/2/202406:30GLOBEArbutus Reports Fourth Quarter and Year End 2023 Financial..
15/2/202406:30GLOBEArbutus to Report Fourth Quarter and Year End 2023 Financial..
14/2/202415:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202409:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202418:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202418:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202406:31EDGAR2Form 8-K - Current report
08/1/202406:30GLOBEArbutus Announces 2024 Corporate Objectives and Provides..
04/1/202415:09EDGAR2Form 8-K - Current report
21/11/202307:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/11/202315:02EDGAR2Form 8-K - Current report
08/11/202306:30GLOBEArbutus to Present at Jefferies London Healthcare Conference
07/11/202315:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202306:31EDGAR2Form 8-K - Current report
07/11/202306:30GLOBEArbutus Reports Third Quarter 2023 Financial Results and..
07/11/202306:16EDGAR2Form 8-K - Current report
07/11/202306:15GLOBEArbutus Announces CEO, William Collier, to Retire December..
24/10/202306:30GLOBEArbutus to Report Third Quarter 2023 Financial Results and..
18/10/202306:30GLOBEArbutus to Present at H.C. Wainwright 4th Annual Hepatitis B..
11/10/202307:06EDGAR2Form 8-K - Current report
11/10/202307:05GLOBEArbutus Announces Multiple Abstracts Accepted for..
11/9/202316:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
11/9/202315:16EDGAR2Form 8-K - Current report
11/9/202315:15GLOBEArbutus Announces Pipeline Updates and Dosing of the First..
07/9/202306:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
03/8/202315:18EDGAR2Form S-8 - Securities to be offered to employees in employee..
03/8/202315:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202306:31EDGAR2Form 8-K - Current report
03/8/202306:30GLOBEArbutus Reports Second Quarter 2023 Financial Results..
20/7/202306:30GLOBEArbutus to Report Second Quarter 2023 Financial Results and..
13/7/202315:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202315:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202315:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202315:48EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202315:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202315:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202306:31EDGAR2Form 8-K - Current report
12/7/202306:30GLOBEArbutus Appoints Melissa V. Rewolinski, PhD to its Board of..
10/7/202315:02EDGAR2Form 8-K - Current report
10/7/202315:01GLOBEArbutus Appoints Two New Executives
21/6/202306:30GLOBEArbutus Doses First Patient in Additional Treatment Arm of..
21/6/202301:01GLOBEArbutus Presents Preliminary AB-729 and Pegylated Interferon..
07/6/202301:01GLOBEArbutus to Present AB-729 and AB-836 Data at EASL Congress..

Su Consulta Reciente

NASDAQ
ABUS
Arbutus Biopharma
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados